The ETF Authority for Monday, May 26th, 2003 Volume 2, Issue #21 Published weekly on Sunday evening, The ETF Authority is a short-term swing trading newsletter that can help you profit from some of the most heavily-traded securities on the market -- exchange-traded funds (ETFs). *Please
Note: This
is a fee-paid, subscribers-only newsletter.
Any republication or retransmission of this web page or any of the
contents herein is expressly prohibited. Click on the link below to
subscribe to this newsletter today... We urge all readers to print out this
newsletter each week for maximum benefit... (1.) MARKET SUMMARY ECONOMIC ANALYSIS Alan Greenspan's testimony to Congress on Thursday didn't bring any surprises. He addressed the very real risk of SARS harming the American and global economies and stated that a pickup in economic activity was reasonable to expect, but we do not have enough post-war information as yet to make reliable forecasts. He opined, as I often have in these pages, that the risk of deflation is still greater than the risk of inflation. However, despite this, short-end futures slipped on Thursday, but remained well above key support levels. My opinion remains that the U.S. economy is in very poor shape and that Europe is even worse off (another reason why the back of the Euro's rally versus the dollar is due to be broken soon). The European Central Bank (ECB) is finally starting to realize the risk going forward and has made it seem as if they will cut rates at least one more time. Unfortunately, the ECB is unlikely to ease enough, and in the meantime, Canada continues to be on the rate hike path. Given that Canada is America's largest trading partner, a slowdown there would be damaging to the American economy. After Monday's holiday, we have a pretty busy week of economic data. Consumer confidence is due out on Tuesday and forecasts are calling for yet another spike higher here. Existing home sales are also released on Tuesday and are seen gaining ground. Low and falling interest rates continue to prop up a market that is due to implode as the economy weakens, especially since interest rates will not be able to fall much more as the economy's engine starts to sputter. Durable goods are forecast to slump sharply this month after a surprisingly good showing in the March data. Consensus is for about a -1.2% decline. I expect the actual figure to come in slightly better than that. Thursday begets the second take on Q1 GDP. Better balance of payments data may lead to a marginal improvement from the first estimate of 1.6%. Friday sees Chicago PMI (forecast to edge higher, though I am not so sure that we can exceed April's 47 reading in any meaningful manner). Also due out are University of Michigan consumer confidence plus personal income and spending. Once again, individuals probably spent more than they made. Sooner or later they will have to pay the piper on that one! WHERE DO WE GO FROM HERE?
http://www.StreetAuthority.com/subscribe-etf.htm Below you'll find a table of weekly performance data for all ETFs that I track for this newsletter...
(3.) ETF RELATIVE STRENGTH MONITOR (Note: If you're a first-time reader or you are otherwise unfamiliar with our proprietary ETF Relative Strength Monitor, then please click here for a brief description.) The bond market had a stellar week, as Alan Greenspan signaled that the Fed would buy long-maturity Treasury notes and bonds in an attempt to flatten the yield curve. The Fed feels the yield curve is too steep and it wants to bring borrowing costs down even more because it fears deflation far more than inflation. This will also allow the Fed to possibly hold off on firing its few precious remaining rate cut bullets. The announcement led the 20+ Year Lehman U.S. Government Bond iShares (TLT, $95.85) to jump 2.3% last week. Only the two biotech funds I track -- the Biotech HOLDR (BBH, $115.20) and the Nasdaq Biotech iShares (IBB, $63.69), which I hold in my model portfolio (see below) -- rose more last week. BBH soared an astounding 10.6% last week and is now up 29.0% over the past 13-week period (IBB is ahead 32.3% in the same time and gained an impressive 3.1% last week). I am quite pleased that although the Dow Diamonds (DIA, $86.23 fell, they still managed to outperform both the S&P 500 and the Nasdaq. That was why I chose that index fund for our model portfolio rather than QQQ or SPY. Tumbling in the rankings was the Pharmaceutical HOLDR (PPH, $75.65), which lost -4.7% last week and is ahead just 7.2% in the past 13 weeks. Only three equity-related funds have performed worse. Its 0.2% return during the most recent four-week period ranks it dead last (remember – the strongest fund receives a ranking of "23", while the weakest gets a ranking of "1") across all 23 funds that I track (including the debt market funds). The rest of the rear guard comes largely the from technology sector, although the Retail HOLDR (RTH, $75.85) has also been weakening. Here is this week's ETF Relative Strength Monitor...
Performance Summary: Our first week proved to be a good one for our Model Portfolio, as we easily outperformed the market. The Semiconductor HOLDR (SMH, $27.12), which we shorted, was the second worst performing fund last week. Meanwhile, the Energy SPDR (XLE, $24.12) and the Nasdaq Biotech iShares (IBB, $63.69) were the 2nd and 3rd best equity-linked performers. Going forward, I have only decided to make one adjustment to our portfolio right now: I will sell a June DIA 88 call (DAVFJ, $0.80) as a partial hedge against our long DIA position at Monday's open. I won't mind if we get called on this trade, since I believe the market is set to slip substantially in the short-term. Furthermore, with such a limited amount of time until expiry, the option is going to see some substantial time decay in the coming weeks. There are no margin requirements for the sale since the position is covered by our long DIA position. If you get called, you will wind up selling the current DIA position for a profit of $1.01 and will still receive the option premium. I do see substantial risk that stocks could move lower in the near term. However, I do not yet have a sell signal. I will revise the portfolio with a flash if a deeper correction appears likely to start (or begins). To give you an idea of things I am looking at for the portfolio going forward, here are some possible actions. If the stock market weakens, as I expect it will, then with IBB so overbought, I think it would be risky to hold it much longer. I have targets about 5% higher than here, but with RSI well above 70, if stocks fall sharply, then IBB will probably not have as much of a defensive impact as it has during other recent market declines. However, the Pharmaceutical HOLDR (PPH), which is oversold, would become favored. Therefore, I will likely switch out of IBB once it reaches its upside potential, or if stocks start falling more quickly. Additionally, a reversal in equities will have me move to short QQQ or SPY as well and close out our long DIA position. I will not do that until I have a clear sell signal. Once the bond market corrects a bit, I would also like to initiate a long position in the 20+ Year Lehman U.S. Government Bond iShares (TLT). If I am wrong, and equities continue their gains, then I
will shift our SMH position to a LONG position and will exit DIA and
purchase QQQ instead. I will also look at a long position in the Financial
SPDR (XLF, $23.61), which tends to act well in an up market.
SELL SHORT 1,000 SHARES TECHNOLOGY SECTOR SPDR (XLK,
$16.14) ABOVE THE MARKET
I am not going to risk a huge amount of money here, as there is still a chance that equities will manage one more rally (though that is not my preferred stance). And, the poor trading recently in this fund makes it a safer bet. It never managed to reach overbought levels, but did exhibit momentum divergences as it made its new highs. XLK also achieved a price target and then fell from near there. Other reasons for concern are that XLK now is in a sell signal from daily MACD and has not been able to hold above the median Andrews Pitchfork line. A break beneath the lower blue line shown (at $15.66 on Monday and rising about $0.05 per day) would confirm a reversal of the uptrend would signal that a deep correction (or worse) may be underway. I like this trade because:
******************************************** SELL SHORT 1,000 SHARES TECHNOLOGY SPDR (XLK, $16.14) AT $16.26 OR BETTER (DO NOT SELL IF IT GAPS OPEN ABOVE $16.39) TARGET: $15.26 Assuming a sale at $16.26, your
profit would be $1,000, or +6.15%. If stopped, assuming a sale at $16.26,
your loss would be just $280, or -1.72%. (6.) CONTINUED GUIDANCE ON PREVIOUS TRADES LONG SIX (6) NASDAQ 100 TRUST
(QQQ, $28.10) SEPTEMBER 2003 27 PUTS (QAVUA, $1.30)
QQQ remains in a weak position. Many of its technicals are similar to the XLK trade described above. We have momentum divergences, targets achieved and one five-wave leg lower completed. Another leg down is due. Resistance is heavy from $28.39 to $28.62. This position is currently down $0.10, or $60.00. --------------------------------- SELL SHORT ISHARES RUSSELL-2000
GROWTH FUND (IWO, $44.25) AT $46.75 IWO never moved up to our entry price, so we have not yet taken this trade. I have now decided to cancel this recommendation. ---------------------------------
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ABOUT OUR
EMAIL POLICY You are receiving this email because you visited StreetAuthority.com and subscribed to our premium ETF AUTHORITY service. This newsletter is sent out only to paid subscribers and limited-time free-trial members. If you feel you have received this issue in error, or if this email was forwarded to you without our express written permission, please contact us by visiting our web site at the link below. We sincerely hope that you benefit from your subscription to our
premium ETF AUTHORITY service, and we’re willing to do
whatever it takes to keep you as a satisfied customer. If at any time you
would like to contact us (for example, to make a recommendation or to
inquire about your account), you can do so by visiting our web site at ADVERTISING INFORMATION ===================================== DISCLAIMER The information contained herein does not constitute a representation by the publisher or a solicitation for the purchase or sale of securities. Our opinions and analyses are based on sources believed to be reliable and are written in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy or completeness. All information contained in this report should be independently verified with the companies mentioned. The editor and publisher are not responsible for errors or omissions. StreetAuthority receives no compensation of any kind from any companies that may be mentioned in our newsletters or on our web site. Any opinions expressed are subject to change without notice. Owners, employees and writers may hold positions in the securities that are discussed in this report or on our web site, but are barred from trading any of these securities seven days before and after the initial publication of this report in accordance with our company policies. (c) Copyright 2003. StreetAuthority LLC and Poser
Global Market Strategies Inc. |